2022
Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Wolf RM, Cheng P, Gal RL, Beaulieu LC, Kollman C, Isganaitis E, Magge S, Mastrandrea LD, Klingensmith GJ, Tamborlane W, Van Name M, Consortium P. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes 2022, 23: 439-446. PMID: 35138021, DOI: 10.1111/pedi.13325.Peer-Reviewed Original ResearchConceptsIntensive lifestyle interventionTreatment failureType 2 diabetesDiabetes medicationsLifestyle interventionGlycemic controlDiscontinuation of insulinExperienced treatment failureInitial insulin treatmentYouth-onset T2DHigh rateMetformin monotherapyPrimary outcomeMedian timeRisk factorsInsulin treatmentMetforminProgressive natureConsortium studyLogistic regressionInsulinT2DIntensive lifestyleMedicationsDiabetes
2019
Pharmacologic treatment options for type 1 diabetes: what’s new?
Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV. Pharmacologic treatment options for type 1 diabetes: what’s new? Expert Review Of Clinical Pharmacology 2019, 12: 471-479. PMID: 30892094, PMCID: PMC6488361, DOI: 10.1080/17512433.2019.1597705.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdjunctive therapyType 1 diabetesInsulin analoguesMimic physiologic insulin secretionGLP-1 receptor agonistsPhysiologic insulin secretionPharmacologic treatment optionsDPP-4 inhibitorsType 2 diabetesVariety of insulinBiosynthetic human insulinPotential adverse effectsSGLT1/2 inhibitorsBasal insulinPharmacologic treatmentTreatment optionsReceptor agonistInsulin secretionSGLT-2Abnormal physiologyProlonged durationTherapyDiabetesInsulinNovel drugsReversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes Technology & Therapeutics 2019, 21: 101-104. PMID: 30688521, PMCID: PMC6434586, DOI: 10.1089/dia.2018.0356.Peer-Reviewed Original ResearchConceptsType 1 diabetesFree fatty acidsSGLT2i useAspart insulinSGLT2 inhibitor therapyPlasma glucose levelsSodium-glucose cotransporterCanagliflozin treatmentEuglycemic DKARescue therapyBasal insulinInhibitor therapyRate of ketogenesisRescue treatmentBlunted increaseSubcutaneous injectionGlucose levelsTreatment studiesNormal increaseInsulinDiabetesTherapyKetogenesisFatty acidsTreatment
2018
The present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent use
2017
Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin
Tamborlane WV, Pfeiffer KM, Brod M, Nikolajsen A, Sandberg A, Peters AL, Van Name M. Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin. Current Medical Research And Opinion 2017, 33: 639-645. PMID: 28008782, DOI: 10.1080/03007995.2016.1275937.Peer-Reviewed Original ResearchConceptsBolus insulinDose timingBolus insulin therapyPrevious weekType 2 diabetesExperiences of peopleInsulin therapyTreatment optionsDiabetes educationWeb-based surveyType 1DiabetesMajority of respondentsInsulinSelf-report surveyGeneralizability of findingsT2DT1DMealWeeksHypoglycemiaRespondentsTherapyBolusPotential bias
2016
Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Tichy EM, Weyman K, Weinzimer SA, Tamborlane WV, Sherr JL. Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study. Diabetes Technology & Therapeutics 2016, 18: 794-799. PMID: 27996320, PMCID: PMC5178000, DOI: 10.1089/dia.2016.0311.Peer-Reviewed Original ResearchConceptsClosed-loop insulin deliveryPlasma glucoseEnd of exercisePG levelsExercise studiesInsulin deliveryExercise periodCL insulin deliveryExercise-induced loweringType 1 diabetes subjectsExercise-induced reductionRecovery periodBrisk treadmillDL increaseRescue treatmentDiabetes subjectsInsulin infusionExerciseInsulinSimilar differencesVisitsCL controlDeliveryGlucosePeriod
2015
Moving toward the ideal insulin for insulin pumps
Cengiz E, Bode B, Van Name M, Tamborlane WV. Moving toward the ideal insulin for insulin pumps. Expert Review Of Medical Devices 2015, 13: 57-69. PMID: 26560137, DOI: 10.1586/17434440.2016.1109442.Peer-Reviewed Original ResearchConceptsTime-action profileGlycemic controlInsulin formulationsRapid-acting insulin analoguesPhysiologic insulin profilesOptimal glycemic controlInsulin pump therapyNew insulin formulationsQuality of lifeContinuous glucose monitoringRegular insulinPump therapyInsulin profilesPharmacological advancesDiabetes managementInsulin analoguesInsulin absorptionInsulin pumpGlucose monitoringInsulin deliveryPump systemTherapyInsulinDelivery methodsDiabetes
2014
Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose
Sherr JL, Collazo M, Cengiz E, Michaud C, Carria L, Steffen AT, Weyman K, Zgorski M, Tichy E, Tamborlane WV, Weinzimer SA. Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose. Diabetes Care 2014, 37: 773-779. PMID: 24170766, PMCID: PMC3931387, DOI: 10.2337/dc13-1608.Peer-Reviewed Original ResearchConceptsBlood β-hydroxybutyrate levelsΒ-hydroxybutyrate levelsBasal insulinBlood glucose levelsBasal insulin infusionGlucose levelsBlood glucoseInsulin infusionMorning blood glucose levelsType 1 diabetic subjectsUsual basal ratesBasal rateLow glucose levelsSignificant ketonemiaDiabetic ketoacidosisDiabetic subjectsControl nightSensor-augmented pump systemGlucose valuesType 1Experimental nightInsulinLow glucoseNext morningInfusion
2013
Insulin pumps in children with T1DM—we told you so
Tamborlane WV, Sherr JL. Insulin pumps in children with T1DM—we told you so. Nature Reviews Endocrinology 2013, 9: 629-630. PMID: 24080733, DOI: 10.1038/nrendo.2013.190.Peer-Reviewed Original Research
2012
The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA. The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin. Diabetes Care 2012, 35: 690-692. PMID: 22374642, PMCID: PMC3308292, DOI: 10.2337/dc11-0732.Peer-Reviewed Original ResearchConceptsType 1 diabetesDetemir insulinInsulin analoguesInsulin pharmacodynamicsRapid-acting insulin analoguesRapid-acting insulinTime-action profileEuglycemic glucose clampCommon regimenRandomized studyDaily injectionsUnits/Glucose clampInsulin actionSame syringePharmacodynamicsAspartInsulinDiabetesRandom orderAdverse effectsSeparate injectionsAction studiesInjectionMixed injectionInsulin Therapy in Children and Adolescents
Tamborlane WV, Sikes KA. Insulin Therapy in Children and Adolescents. Endocrinology And Metabolism Clinics Of North America 2012, 41: 145-160. PMID: 22575411, DOI: 10.1016/j.ecl.2012.01.002.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsContinuous insulin infusionInsulin therapyBasal-bolus therapyMainstay of treatmentInsulin replacement therapyType 2 diabetesType 1 diabetesDaily injectionsReplacement therapyAnalogue insulinInsulin infusionInsulin secretionBiosynthetic humanTherapyInsulin formulationsNormal patternDiabetesTreatmentChildrenAdolescentsInfusionAimMainstayInsulin
2011
New-generation diabetes management: glucose sensor-augmented insulin pump therapy
Cengiz E, Sherr JL, Weinzimer SA, Tamborlane WV. New-generation diabetes management: glucose sensor-augmented insulin pump therapy. Expert Review Of Medical Devices 2011, 8: 449-458. PMID: 21728731, PMCID: PMC3177536, DOI: 10.1586/erd.11.22.Peer-Reviewed Original ResearchConceptsSensor-augmented insulinSensor-augmented insulin pump therapyCommon chronic disorderInsulin pump therapyContinuous subcutaneous insulin infusion systemsInsulin infusion systemField of diabetesPump therapyGlucose variabilityChronic disordersChallenging diseaseContinuous glucose monitorDelivery of insulinDiabetes managementInfusion systemTherapyInsulin deliveryTechnologic advancesInsulin
2008
Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes
White NH, Chase HP, Arslanian S, Tamborlane WV, . Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes. Diabetes Care 2008, 32: 387-393. PMID: 19106380, PMCID: PMC2646014, DOI: 10.2337/dc08-0800.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsInsulin glargineType 1 diabetesGlucose variabilityLente insulinPediatric patientsDaily injectionsBasal insulin componentOpen-label studySubset of patientsContinuous glucose monitoring systemMDI regimenGlucose monitoring systemGlycemic excursionsInsulin componentInsulin lisproContinuous glucose monitoring dataGlargineGlucose valuesGlucose monitoring dataType 1PatientsInsulinGreater reductionDiabetes
2006
Fulfilling the promise of insulin pump therapy in childhood diabetes
Tamborlane WV. Fulfilling the promise of insulin pump therapy in childhood diabetes. Pediatric Diabetes 2006, 7: 4-10. PMID: 16774611, DOI: 10.1111/j.1399-543x.2006.00171.x.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoring systemContinuous subcutaneous insulin infusion (CSII) treatmentType 1 diabetes mellitusRapid-acting insulin analoguesTreatment of T1DMComplications TrialDiabetes mellitusDiabetes controlGlucose monitoring systemChildhood diabetesFavorable outcomeInsulin analoguesInfusion treatmentInsulin pumpTherapyMinimal riskT1DMDiabetesInsulinTreatmentMellitusHypoglycemiaCSIIRecent introduction
2003
The influence of insulin on circulating ghrelin
Flanagan DE, Evans ML, Monsod TP, Rife F, Heptulla RA, Tamborlane WV, Sherwin RS. The influence of insulin on circulating ghrelin. AJP Endocrinology And Metabolism 2003, 284: e313-e316. PMID: 12531744, DOI: 10.1152/ajpendo.00569.2001.Peer-Reviewed Original ResearchConceptsGhrelin productionGrowth hormone secretagogue receptorSuppression of ghrelinAction of ghrelinHyperglycemic glucose clampInfluence of insulinGhrelin releaseGhrelin levelsGH responseGH secretionGH axisInsulin infusionSecretagogue receptorGlucose clampGhrelinHypoglycemiaEnergy homeostasisPhysiological regulatorSignificant riseInsulinGHNovel peptideAdditional effectClampGlucose
2002
Insulin pump therapy in the 21st century
Bode BW, Tamborlane WV, Davidson PC. Insulin pump therapy in the 21st century. Postgraduate Medicine 2002, 111: 69-77. PMID: 12040864, DOI: 10.3810/pgm.2002.05.1200.Peer-Reviewed Original Research
1994
Metabolic Effects of rhIGF-1 in Normal Human Subjects
Rennert NJ, Boulware SD, Kerr D, Caprio S, Tamborlane WV, Sherwin RS. Metabolic Effects of rhIGF-1 in Normal Human Subjects. Advances In Experimental Medicine And Biology 1994, 343: 311-318. PMID: 8184741, DOI: 10.1007/978-1-4615-2988-0_30.Peer-Reviewed Original ResearchConceptsRhIGF-1Hepatic glucose productionIGF-1Free fatty acidsGlucose productionGlucose uptakeEuglycemic clamp techniqueHuman IGF-1Normal human subjectsSpite of maintenanceSustained euglycemiaMetabolic effectsFFA levelsHypoglycemic effectClamp techniqueMetabolic actionsProfound reductionInsulinHypoglycemic hormoneFat cellsRatsComparable stimulationProtein breakdownSimilar extentEuglycemia
1991
SUPPRESSION OF COUNTERREGULATORY HORMONE RESPONSE TO HYPOGLYCEMIA BY INSULIN PER SE
DIAMOND M, HALLARMAN L, STARICK-ZYCH K, JONES T, CONNOLLY-HOWARD M, TAMBORLANE W, SHERWIN R. SUPPRESSION OF COUNTERREGULATORY HORMONE RESPONSE TO HYPOGLYCEMIA BY INSULIN PER SE. The Journal Of Clinical Endocrinology & Metabolism 1991, 72: 1388-1390. PMID: 2026760, DOI: 10.1210/jcem-72-6-1388.Peer-Reviewed Original ResearchConceptsCounterregulatory hormone responsesHormone responseGlucose levelsNormal subjectsCounterregulatory hormone levelsResponses of epinephrineVariable glucose infusionDegree of hyperinsulinemiaHigh-dose studiesHypoglycemic clamp studiesHypoglycemic counterregulationHypoglycemic stimulusInsulin doseExogenous insulinDose studyHormone levelsGlucose infusionClamp studiesHypoglycemiaGrowth hormoneHypoglycemic plateauInsulinModulating effectOnly variableHyperinsulinemiaMetabolic effects of IGF-I and insulin in spontaneously diabetic BB/w rats
Jacob RJ, Sherwin RS, Bowen L, Fryburg D, Fagin KD, Tamborlane WV, Shulman GI. Metabolic effects of IGF-I and insulin in spontaneously diabetic BB/w rats. American Journal Of Physiology 1991, 260: e262-e268. PMID: 1996629, DOI: 10.1152/ajpendo.1991.260.2.e262.Peer-Reviewed Original ResearchConceptsBB/W ratsBeta-hydroxybutyrate levelsDiabetic ratsNondiabetic ratsGlucose uptakeW ratsDiabetic BB/W ratsGlucose productionInsulin-like growth factor IIGF-I infusionDiabetic BB ratsInsulin-dependent diabetesMetabolic responseGrowth factor IHepatic glucose productionInsulin-stimulated glucose uptakeGlucose production rateBB ratsMetabolic effectsSimilar twofold increaseIGFRatsFactor IInsulinKetone concentrations
1989
Oxidative fuel metabolism during mild hypoglycemia: critical role of free fatty acids
Caprio S, Gelfand RA, Tamborlane WV, Sherwin RS. Oxidative fuel metabolism during mild hypoglycemia: critical role of free fatty acids. American Journal Of Physiology 1989, 256: e413-e419. PMID: 2646946, DOI: 10.1152/ajpendo.1989.256.3.e413.Peer-Reviewed Original ResearchConceptsFree fatty acidsCarbohydrate oxidationFuel metabolismGlucose uptakeInsulin-induced fallInsulin-induced hypoglycemiaFatty acidsMild hypoglycemiaCatecholamine releaseMild hyperinsulinemiaAddition of heparinNormal subjectsFat oxidationTransient decreaseGlucose productionGroup of studiesHypoglycemiaInsulinPropranololEarly riseHeparinGlucose concentrationBase lineMetabolismLatter changes